Why the study?
While sustained ACEI/ARB therapy has no harmful effects in COVID-19 patients with hypertension, the impact of discontinuing ACEIs/ARBs in this population required investigation.
Does discontinuing ACEIs/ARBs and switching to calcium channel blockers prolong hospital stay in moderate to severe COVID-19 patients with hypertension?
Does discontinuing ACEIs/ARBs and switching to calcium channel blockers prolong hospital stay in moderate to severe COVID-19 patients with hypertension?
Discontinuing ACEIs/ARBs and switching to calcium channel blockers in moderate-to-severe COVID-19 patients with hypertension is associated with prolonged hospital stays.
Answers are grounded in this paper and cite their sources.
ACEI/ARB discontinuation was associated with longer COVID-19 stays; leaves open optimal antihypertensive choice and requires randomized confirmation.
BACKGROUND: Recent studies have revealed that sustained ingestion of angiotensin converting enzymes inhibitors or angiotensin receptor blockers (ACEIs/ARBs) had no harmful effects on coronavirus disease 2019 (COVID-19) patients complicated with hypertension. AIM: To investigate the impact on COVID-19 patients complicated with hypertension who discontinued using ACEIs/ARBs. METHODS: All COVID-19 patients complicated with hypertension admitted to our isolated unit were consecutively recruited in this study. Some patients switched from ACEIs/ARBs to calcium channel blocker (CCBs) after admission, while others continued using non-ACEIs/ARBs. We compared characteristics and clinical outcomes between these two groups of patients. CONCLUSION: Patients in the discontinued ACEIs/ARBs group had longer hospital stays. Our findings suggest that COVID-19 patients complicated with hypertension should continue to use ACEIs/ARBs.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: